当前位置:
首页>产品中心>单抗/多抗>Anti-Durvalumab Polyclonal Antibody|抗度伐利尤单抗多克隆抗体(靶标:度伐利尤单抗(抗PD-L1单抗))
Anti-Durvalumab Polyclonal Antibody|抗度伐利尤单抗多克隆抗体(靶标:度伐利尤单抗(抗PD-L1单抗))
- 货号:RB9T37024648
- 价格:面议
- 点击:450
产品介绍
产品参数
| 形态 | Liquid |
|---|
| 宿主种属 | Rabbit |
|---|
| 克隆性 | Polyclonal |
|---|
| 抗体亚型 | IgG |
|---|
| 纯化方式 | Purified by antigen affinity column. |
|---|
| 内毒素水平 | Please contact with the lab for this information. |
|---|
| 应用 | ELISA |
|---|
| 特异性 | The product is specific for Durvalumab. This antibody serves as an excellent positive control for Durvalumab immunogenicity (ADA) assays. |
|---|
| 靶标 | Rabbit polyclonal antibody to Imfinzi. |
|---|
| 免疫原 | Durvalumab |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
|---|
| 稳定性和储存 | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
|---|
| 产品使用说明 | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
|---|
| 登录号 | CAS: 1428935-60-7 |
|---|
| 背景信息 | Durvalumab (Imfinzi) is a human IgG1 monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.Antibodysystem Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.
|
|---|
| 备注 | For research use only. |
|---|
【仅供科学研究使用】
相关产品: